Medicalgorithmics SA

As of March 31, 2026, Medicalgorithmics SA carries a market capitalization of 277.18M, placing it among publicly traded companies globally. Its enterprise value stands at 296.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medicalgorithmics SA's next confirmed earnings release is scheduled for November 26, 2026.

As of March 31, 2026, Medicalgorithmics SA has 9.95M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 8.04, and the price-to-book ratio stands at 4.41.

These figures are as of March 31, 2026. The EV/Sales ratio of 8.61 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 296.67M versus a market cap of 277.18M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Medicalgorithmics SA maintains a current ratio of 1.11, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 35.00, indicating elevated leverage, while an interest coverage ratio of -0.38 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Medicalgorithmics SA posted a negative return on equity (ROE) of -14.21, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -8.91, reflecting losses generated across the asset base. The company generates approximately 304,858.41 in revenue per employee across its workforce of 113.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.56 indicates how many times Medicalgorithmics SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Medicalgorithmics SA recorded 600,000.00 in income tax expense. The company reported a pretax loss of -9.02M and -9.63M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Medicalgorithmics SA's stock has declined approximately 33.00% over the past 52 weeks. The 50-day moving average sits at 26.19, while the 200-day moving average is 28.30.

Over the twelve months ended March 31, 2026, Medicalgorithmics SA generated 34.45M in revenue and converted that into -9.63M in net income, yielding earnings per share of -0.97. EBITDA reached -964,000.00, while operating income came in at -4.75M.

As of March 31, 2026, Medicalgorithmics SA holds 2.57M in cash and equivalents against 22.03M in total debt, resulting in a net debt position of 19.46M. Total book value stands at 62.92M, with working capital of 1.73M providing operational flexibility.

Medicalgorithmics SA produced -198,000.00 in operating cash flow over the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Medicalgorithmics SA posted a gross margin of 89.56, reflecting its pricing power and cost economics. The operating margin of -13.80 and net profit margin of -27.96 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -0.07: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.24, meaning Medicalgorithmics SA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2026, Medicalgorithmics SA has an Altman Z-Score of -5.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.